Emerging drugs for migraine prophylaxis and treatment

MedGenMed Medscape General Medicine

Volumn 8, Issue 2, 2006, Pages

  Bigal, Marcelo E ^a,b   Krymchantowski, Abouch V ^c,d  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Instituto de Neurologia Deolindo Couto   (Brazil)

^d Headache Center of Rio de Janeiro   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; ANTIINFLAMMATORY AGENT; BOTULINUM TOXIN; CAPSAICIN; CARVEDILOL; CIS CAPSAICIN; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; ETIRACETAM; GR 190178; LNMAH 546C88; NITRIC OXIDE SYNTHASE INHIBITOR; OLCEGEPANT; PETASITES HYPRIDUS EXTRACT; PLACEBO; PLANT EXTRACT; PNU 142633; QUETIAPINE; RIZATRIPTAN; SEROTONIN 1B AGONIST; SUMATRIPTAN; TIAGABINE; TIZANIDINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZOLMITRIPTAN; ZONISAMIDE; DRUG DERIVATIVE; FRUCTOSE;

ABDOMINAL PAIN; ADD ON THERAPY; ANOREXIA; APHASIA; ASTHENIA; ATAXIA; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CHRONIC DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; COMMON COLD; CONFUSION; DELUSION; DEPRESSION; DIARRHEA; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DYSPHORIA; ECONOMIC ASPECT; FATIGUE; HUMAN; INCIDENCE; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; LIVER DYSFUNCTION; MIGRAINE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATHOPHYSIOLOGY; PETASITES; PETASITES HYPRIDUS; PHYSICAL DISABILITY; PREVALENCE; PROPHYLAXIS; PTOSIS; QT PROLONGATION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOCIAL ASPECT; SOMNOLENCE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TABLET FORMULATION; TASTE AVERSION; THORAX PAIN; TREMOR; UPPER RESPIRATORY TRACT INFECTION; UROLITHIASIS; VISUAL IMPAIRMENT; WEIGHT REDUCTION;

FRUCTOSE; HUMANS; MIGRAINE DISORDERS;

EID: 33646805362     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity, and attack frequency and duration. Neurology. 1994;44:S24-S39.
2. Goadsby PJ. Pathophysiology of migraine. In: Silberstein SD, Lipton RB, Dalessaio DJ (eds.) Wolff's Headache and Other Head Pain. 7th ed. Oxford: Oxford University Press, 2001:57-72.
3. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiology implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999; 19:115-127. Abstract
4. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002;346:257-270. Abstract
5. Welch KMA, Barkley GL, Tepley N, et al. Central neurogenic mechanisms of migraine. Neurology. 1993;43:S21-S25.
6. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19-26. Abstract
7. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20:765-786. Abstract
8. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based rev Neurology. 2000;55:754-763. Abstract
9. Dodick DW. Acute and prophylactic management of migraine. Clin Cornerstone. 2001;4:36-52. Abstract
10. Ramadan MN, Silberstein SD, Freitag FG, Gilbert TT, Frishberg GM. Pharmacological management for prevention of migraine. Available at: http://www.aan.com/public/practiceguidelines/ Accessed July 2005.
11. Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache. 2004;44:661-668. Abstract
12. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668-1675. Abstract
13. Matchar DB, Young WB, Rosenerg J, et al. Multispecialty consensus on diagnosis and treatment of headache: pharmacological management of acute attacks. Neurology. 2000;54. Available at: www.aan.com/public/practiceguidelines/ Accessed July 2005.
14. Bigal ME, Lipton RB, Krymchantowski AV. The medical management of migraine. Am J Ther. 2004;11:130-140. Abstract
15. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes Epilepsia 2000;41:35-39.
16. Sigel E. Functional modulation of ligand-gated GABAA and NMDA receptor channels by phosphorilation. J Receptor Signal Transduct Res. 1995;15:325-332.
17. Gibbs JW, Sombati S, Delorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainite-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000;41:S10-S16.
18. Shuaib A, Ahmed F, Muratoglu M, Kochanski P. Topiramate in migraine prophylaxis: a pilot study. Cephalalgia 1999;19:379-380.
19. Silberstein SD, Neto W, Schmitt J, Jacobs D; Migr-001 Study Group. Topiramate in migraine prevention: result large controlled trial. Arch Neurol. 2004;61:490-495. Abstract
20. Brandes JL, Saper JR, Diamond M, et al; Migr-002 Study Group. Topiramate for migraine prevention: a randor controlled trial. JAMA. 2004;291:965-973. Abstract
21. Campistol J, Campos J, Casas C, Herranz JL. Topiramate in the prophylactic treatment of migraine in children J Child Neurol. 2005;20:251-253. Abstract
22. Pelloch JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving anti-epileptic drugs. Neurology. 1991;41:961-964. Abstract
23. Drake ME Jr, Kay AM, Knapp MS, et al. An open-label trial of tiagabine for migraine prophylaxis. Headache. 1999;39:352.
24. Freitag FG, Diamond S, Diamond ML, et al. The prophylaxis of migraine with the GABA-agonist, tiagabine: a clinical report. Headache. 1999;39:354.
25. Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent model of seizures and epilepsy. Eur J Pharmacol. 1998;353:191.
26. Nicolas J-M, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Disp. 1999;27:250-254.
27. Drake ME, Greathouse NI, Armentbright AD, Renner JB. Levetiracetam for preventive treatment of migraine. Cephalalgia. 2001;21:373.
28. Krusz JC. Levetiracetam as prophylaxis for resistant headaches. Cephalalgia. 2001;21:373.
29. Rapoport AM, Sheftell FD, Tepper SJ, Bigal ME. Levetiracetam in the preventive treatment of transformed migraine. Curr Ther Res. 2005;66:212-221.
30. Vaisleb I, Neft R, Schor N. Role of Levetiracetam in prophylaxis of migraine headaches in childhood. Neurology. 2005;64:A343.
31. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: A Europe double-blind trial. Epilepsy Res. 1993;15:67-73. Abstract
32. Ito T, Hori M, Kadokawa T. Effects of zonizamide (AD-810) on tungistic acid gel-induce thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharge in cats. Epilepsia. 1986;27:367-374. Abstract
33. Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies: our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry. 1992;16:79-85. Abstract
34. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit. 1998;20:593-597. Abstract
35. Krusz JC. Zonisamide in the treatment of headache disorders. Cephalalgia. 2001;21:374-375.
36. Drake ME, Greathouse NI, Armentbright AD, Renner JB. Preventive treatment of migraine with zonisamide. Cephalalgia. 2001;21:374.
37. Eaton J. Butterbur, herbal help for migraine. Nat Pharm. 1998;2:23-24.
38. Lin H, Chien CH, Lin YL, et al. Inhibition of testosterone secretion by S-petasin in rat testicular interstitial cells. J Physiol. 2000;43:99-103. Abstract
39. Grossmann M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int. J Clin Pharmacol Ther. 2000;38:430-435. Abstract
40. Lipton RB, Gobel H, Wilks K, Mauskop A. Efficacy of petasites (an extract from Petasites rhizone) 50 and 75 mg for prophylaxis of migraine: results of a randomized, double-blind, placebo controlled study (abstract). Neurology. 2002;58:A472.
41. Cleophus TJ, Zwinderman AH. Beta-blockers and heart failure: meta-analysis of mortality trials. Int J Clin Pharm Ther. 2001;39:383-387.
42. Kaniecki RG. Migraine prevention with Carvedilol: a prospective, open-label trial. Headache. 2003;43:589.
43. Zaimis E, Hanington E. A possible pharmacological approach to migraine. Lancet. 1969;2:298-300. Abstract
44. D'Andrea G, Perini F, Granella F, Cananzi A, Sergi A. Efficacy of transdermal clonidine in the treatment of cluster headache. In: Olesen J, Tfelt-Hansen P, eds. Headache Treatment. Trial Methodology and New Drugs. Philadelphia, Pa: Lippincott-Raven; 1997:335-340.
45. Saper JR, Lake AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double blind, placebo controlled, multicenter outcome study. Headache. 2002;42:470-482. Abstract
46. Krusz JC, Belanger J, Mills C. Tizanidine: a novel effective agent for the treatment of chronic headaches. Headache. 2000;11:41-45.
47. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine and quetiapine. Am J Psychiatry. 1999;156:876-884. Abstract
48. Schatzberg AF, Cole JO, Debattista C. Manual of Clinical Psychopharmacology. 4th ed. Washington, DC: American Psychiatric Publishing; 2002:199-200.
49. Brandes JL, Roberson SC, Pearlamn SH. Quetiapine for migraine prophylaxis. Headache. 2002;42:450-451.
50. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cel botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35-42. Abstract
51. Volknandt W. Commentary: the synaptic vesicle and its targets. Neuroscience. 1995;64:277-300. Abstract
52. Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW. Treatment of headache with botulinum toxin A - a review according to evidence-based medicine criteria. Cephalalgia. 2002;22:699-710. Abstract
53. Silberstein SD, Mathew NT, Saper J, Jenkins S; Botox Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000;40:445-450. Abstract
54. Ondo W, Vuong K, Derman H. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled parallel-design study. Cephalalgia. 2004;24:6-15.
55. Humphrey PPA, Goadsby PJ. Controversies in headache. The mode of action of sumatriptan is vascular? A debate. Cephalalgia. 1994;14:401-410. Abstract
56. Maassen Vandenbrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98:25-30. Abstract
57. Buchanan TM, Ramadan NM, Aurora S. Future pharmacologic targets for acute and preventive treatments of migraine. Expert Rev. Neurother. 2004;4:391-430.
58. Mccall RB, Huff R, Chio CL, et al. Preclinical studies characterizing the antimigraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633. Cephalalgia. 2002;22:799-806. Abstract
59. Fleishaker JC, Pearson LK, Knuth DW, et al. Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633. Int J Clin Pharmacol Ther. 1999;37:487-492. Abstract
60. Gomez-Mancilla B, Cutker NR, Leibowitz MT, et al. Safety and tolerability of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia. 2001;21:727-732. Abstract
61. Adham N, Kao HT, Schecter LE, et al. Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993;90:408-412. Abstract
62. Shepheard S, Edvinsson L, Cumberbatch M, et al. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia. 1999;19:851-858. Abstract
63. Phebus LA, Johnson KW, Zgombick JM, et al. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 1997;61:2117-2126. Abstract
64. Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT(1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001;358:1230-1234. Abstract
65. Reeve AJ, Dickenson AH. The roles of spine adenosine receptors in the control of acute and more persistent nociceptive responses of dorsal horn neurons in the anesthetized rats. Br J Pharmacol. 1995;116:2221-2228. Abstract
66. Schindler M, Harris CA, Hayes B, Papotti M, Humphrey PP. Immunohistochemical localization of adenosine A 1 receptors in human brain regions. Neurosci Lett. 2001;297:211-215. Abstract
67. Gurden MF, Coates J, Ellis F, et al. Functional characterization of three adenosine receptor subtypes. Br J Pharmacol. 1993;109:693-698. Abstract
68. Bland-Ward PA, Fentiuk W, Humphrey PPA. The adenosine A1 receptor agonist GR79236 inhibits evoked firing trigeminal nucleus caudalis (TNC) neurons in the rat. Cephalalgia. 2000;20:271-274.
69. Goadsby PJ, Hoskin KL, Storer RJ, Edvinsson L, Connor HE. Adenosine (A1) receptor agonists inhibit trigeminovascular nociceptive transmission. Brain. 2002;125:1392-1401. Abstract
70. Giffin NJ, Kowacs F, Libri V, et al. Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy humans subjects. Cephalalgia. 2003;23:287-292. Abstract
71. Hou M, Uddman R, Tajti J, Kanje M, Edvinsson L. Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Neurosci Lett. 2002;330:223-226. Abstract
72. Markowitz S, Saito K, Moskowitz M. Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. Neurosci. 1987;7:4129-4136.
73. Diamond S, Freitag F, Phillips S, Bernstein J, Saper J. Intranasal civamide for the acute treatment of migraine headache. Cephalalgia. 2000;20:597-602. Abstract
74. Jansen-Olesen I, Jorgensen L, Engel U, Edvinsson L. In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol. 2003;481:207-216. Abstract
75. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193-196. Abstract
76. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology. 1993;43:S16-S20. Abstract
77. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183-187. Abstract
78. Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129:420-423. Abstract
79. Iovino M, Feifel U, Young CL, Wolters JM, Wallestein G. Safety, tolerability and pharmacokinetics of BIBN4096BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia. 2004;24:645-656. Abstract
80. Olesen J, Diener HC, Husstedt IW, et al. BIBN4096BS Clinical Proof of Concept Study. Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104-1110. Abstract
81. Bereiter DA, Benetti AP. Excitatory amino acid release within spinal trigeminal nucleus after mustard oil injection into the temporomandibular joint region of the rat. Pain. 1996;67:451-459. Abstract
82. Fundytus ME. Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs. 2001;15:29-58. Abstract
83. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48:1212-1218. Abstract
84. Sang CN, Hostetter MP, Gracely RH, et al. AMPA/kainite antagonist LY-293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology. 1998;89:1060-1067. Abstract
85. Sang CN, Ramadan NM, Wallihan RG, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and web-tolerated in acute migraine. Cephalalgia. 2004;24:596-602. Abstract
86. Tassorelli C, Joseph SA, Buzzi MG, Nappi G. The effects on central nervous system of nitroglycerine - putative mechanism and mediators. Prog Neurobiol. 1999;57:607-624. Abstract
87. Read SJ, Smith MI, Hunter AJ, Parsons AA. Enhanced nitric oxide release during cortical spreading depression following infusion of glyceryl trinitrate in the anesthetized cat. Cephalalgia. 1997;17:159-165. Abstract
88. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity. A possible molecular mechanism of migraine Neuroreport. 1993;4:1027-1030. Abstract
89. Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia. 1998;18:27-32. Abstract
90. Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J. The effect of nitric oxide synthase inhibition histamine induced headache and arterial dilatation in migraineurs. Cephalalgia. 2003;23:877-886. Abstract
91. Ashina A, Lassen LH, Bendtsen L, Janssen R, Olesen J. Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial. Lancet. 1999;353:287-289. Abstract